Afuco™ Anti-ITGB2 ADCC Therapeutic Antibody (Rovelizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD18. Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-044 |
| Pricing | Inquiry |
| Host | Human |
| Target | ITGB2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | Neut, ELISA, IF, IP, FuncS, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |